Education

Why Specialty Infusion Costs Are Straining Employer Healthcare Budgets

Image

Specialty infusion costs are quietly becoming one of the most significant pressures on employer healthcare budgets, according to a recent Benefit News article authored by Rob LaHayne, co-founder of Leap.

In the piece, LaHayne examines how infusion therapies have evolved from a niche clinical service into a major cost driver for self-funded employers. Over the past decade, the U.S. infusion therapy market has more than doubled, growing from approximately $150 billion in 2015 to over $360 billion in 2025, with pharmacy spending increasingly outpacing overall health benefits growth.

At the same time, where and how infusion care is delivered has remained largely unchanged — with significant implications for cost, access, and employee experience.

Key Takeaways for Employers and Benefits Leaders

The Benefit News article highlights several dynamics reshaping employer healthcare spend:

  • Most infusion care still happens in the highest-cost settings. Roughly 85% of infusions are delivered in hospital outpatient departments or traditional infusion centers, where pricing is often opaque and difficult for employers to manage.
  • Provider markups significantly inflate costs. In hospital-based settings, buy-and-bill pricing can drive the cost of the same infusion drug 400% higher, particularly for high-cost specialty therapies.
  • The financial stakes are substantial. A single infusion dose for certain conditions can exceed $20,000, meaning pricing inefficiencies and site-of-care decisions compound rapidly across a self-funded population.
  • Cost controls often shift the burden to employees. Employers commonly rely on prior authorizations and utilization controls to manage rising spend, which can introduce delays, administrative complexity, and fragmented care for employees managing serious conditions.

A more transparent approach to infusion care

Leap helps self-funded employers reduce specialty infusion costs through transparent pricing and coordinated care.

This post summarizes an article originally published in Employee Benefit News. Read the full article here: https://www.benefitnews.com/opinion/specialty-infusion-drug-costs-are-putting-strain-on-healthcare-spend


Share this post

More insights

Image
News

Leap Posts 25x Growth; Expands Executive Team

NEW YORK, NY — February 4, 2026 — Leap, the leading infusion therapy partner for self-funded employe...

Read article
Image
News

Leap partners with Angle Health to simplify and transform infusion care

Leap has partnered with Angle Health  to make infusion care simpler, more transparent, and less disr...

Read article
Image
Education

The Infusion Cost Crisis: Why Medical Benefit Drug Spend Keeps Escalating

For employers, however, infusion care has quietly become one of the fastest-growing and least unders...

Read article
Image
News

Leap Joins the Castlight Ecosystem to Simplify Infusion Care

Leap has joined the Castlight ecosystem to give TPAs and employers a more transparent, predictable, ...

Read article
Image
Insights

Rebates, what rebates? Understanding pharmacy rebates for J-Code drugs

Pharmacy rebates are manufacturer-paid discounts, typically negotiated behind

Read article
Image
Education

Demystifying Specialty Drug Pricing Acronyms, and Why They All Fail Employers

Behind the exorbitant costs of infusion therapies, you’ll find layers of complexity—and three acrony...

Read article
Image
Clinical

Safely Infusing Immunoglobulin in the Home Setting: Clinical Considerations and Best Practices

Immunoglobulin (Ig) therapies are essential in the treatment of primary immunodeficiency (PID), chro...

Read article
Image
News

Leap and Amwins Partner to Deliver Low-Cost, Convenient Infusion Therapy

Leap and Amwins Rx, today announced a strategic collaboration that will bring significant benefits t...

Read article
Image
Case Study

Bringing Relief Home for Annie

Helping a working parent stay on track with infusion care

Read article
Image
Insights

How Leap Reduces the Total Cost of Multiple Sclerosis Care

For patients requiring long-term MS infusions like Ocrevus or Tysabri, traditional hospital-based tr...

Read article